Study reveals metabolic syndrome’s impact on brain volume and cognitive function
June 24, 2024 / Metabolic Syndrome / Cognitive Function / Vascular Pathology / Disease Prevention
Metabolic syndrome (MetS) is linked to reduced brain volume and cognitive function. The study found that increased MetS components correlate with poorer cognition and vascular pathology, emphasizing MetS as a target for disease prevention strategies.
Cardiovascular Disease in MASH vs. Other Liver Diseases
June 24, 2024 / Metabolic Dysfunction / Cardiovascular Disease / MASH / MASLF / Liver Disease
Patients with metabolic dysfunction-associated steatohepatitis (MASH) have a higher incidence of cardiovascular diseases (CVD) and increased mortality compared to other liver diseases, highlighting the need for aggressive management of cardiovascular risk factors.
Mitochondrial metabolic reprogramming in diabetic kidney disease
June 24, 2024 / Diabetic Kidney Disease / DKD Treatment
Mitochondrial metabolic reprogramming significantly impacts diabetic kidney disease (DKD) by inducing oxidative stress, inflammation, and renal fibrosis. Targeting metabolic reprogramming may offer new therapeutic approaches to delay DKD progression.
Sun Pharma’s Utreglutide shows weight loss, gluco-metabolic and lipid-lowering efficacy
June 24, 2024 / Utreglutide / Obesity Treatment / GLP-1 Receptor Agonist / Weight Loss
Sun Pharma’s Utreglutide (GL0034) demonstrates significant weight loss, improved glucose metabolism, and lipid-lowering effects in obese adults. The Phase 1 study shows promise for managing obesity and related metabolic disorders, with favorable safety and tolerability.
Children born underweight found to be at increased risk of disease if they develop obesity
June 24, 2024 / Childhood Obesity / Cardiometabolic Disease / Insulin Sensitivity / Obesity
Children born underweight face increased health risks, including cardiometabolic diseases, if they develop obesity. This research highlights the need for tailored prevention and treatment approaches for this vulnerable group.
Prevalence and associated factors of metabolic syndrome among pregnant Ethiopian women: a hospital-based cross-sectional study
June 23, 2024 / Metabolic Syndrome / Pregnancy / Women’s Health / Nutrition
A study in Ethiopia found a 13.2% prevalence of metabolic syndrome (MetS) among pregnant women. Key factors associated with MetS were alcohol consumption, high salt intake, and sleep disturbances, emphasizing the need for targeted public health interventions.
Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions
June 22, 2024 / Sun Pharma / Utreglutide Weight Loss / Obesity / Gluco-metabolic Improvement
Sun Pharma’s GL0034 (Utreglutide) demonstrated significant weight loss, improved gluco-metabolic parameters, and lipid-lowering effects in obese individuals during a Phase 1 study. The treatment showed a favorable tolerability profile and potential for addressing obesity and related metabolic disorders.
Nutritious diet may protect against type 2 diabetes, regardless of genetics
June 22, 2024 / Healthy Diet / Type 2 Diabetes / Diabetes Prevention / Blood Glucose Levels
A healthy diet lowers blood glucose levels and reduces the risk of prediabetes and type 2 diabetes, even in individuals with a high genetic predisposition, according to a University of Eastern Finland study.
Late bedtime, insufficient sleep associated with poor cardiometabolic health
June 22, 2024 / Health Risks / Cardiometabolic Health / Hypertension / Metabolic Syndrome
Late bedtime and insufficient or excessive sleep are linked to higher risks of hypertension, hypertriglyceridemia, and metabolic syndrome, particularly in adults aged 40 to 59, according to a study published in the Journal of the American Heart Association.
Weight loss surgery cuts risk of heart complications and death in patients with obstructive sleep apnea and obesity
June 21, 2024 / Bariatric Surgery Benefits / Obesity / Heart Health / Weight Loss
A Cleveland Clinic study found that bariatric surgery significantly reduces the risk of death and major cardiovascular events in patients with obesity and obstructive sleep apnea, demonstrating a 42% lower risk of adverse cardiovascular events and a 37% lower risk of death.
A Mendelian randomization study between metabolic syndrome and its components with prostate cancer
June 21, 2024 / Metabolic Syndrome / Prostate Cancer / Cancer Risk Factors / Genetic Analysis
A Mendelian randomization study found no causal relationship between metabolic syndrome or its components and prostate cancer. The study highlights the need for further research to explore potential connections between these conditions.
Semaglutide weight loss results linked to diabetes severity
June 21, 2024 / Semaglutide Weight Loss / Type 2 Diabetes / Obesity Management
A study found that the effectiveness of semaglutide for weight loss is reduced in patients with severe type 2 diabetes (T2D), as indicated by higher IMS scores. This highlights the need to consider T2D severity when prescribing semaglutide for obesity management.
knownwell acquires Alfie Health to enhance metabolic health offerings
June 21, 2024 / Knownwell Acquisition / Alfie Health / Obesity Management / AI / Metabolic Health
Knownwell acquired Alfie Health to integrate its AI-enabled ObesityRx platform into knownwell’s weight-inclusive primary and metabolic care services, enhancing clinical decision support. This acquisition strengthens knownwell’s infrastructure and value-based care model.
Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases
June 18, 2024 / Marea Therapeutics / Cardiometabolic Disease / Clinical Development
Marea Therapeutics launched with $190 million in funding to develop new cardiometabolic disease treatments. Their lead drug, MAR001, targets ANGPTL4 to lower remnant cholesterol and improve metabolic function, showing promise in early clinical trials.
Exercising at night improves glucose control in overweight adults
June 20, 2024 / Glucose Control / Obesity
A study in Obesity found that evening exercise improves glucose control in overweight and obese adults more effectively than morning or mixed-timing exercise, lowering 24-hour and nocturnal blood glucose levels.
Common dietary emulsifiers promote metabolic disorders and intestinal microbiota dysbiosis in mice
June 20, 2024 / Metabolic Disorders / Dietary Emulsifiers / Obesity
Common dietary emulsifiers such as lecithin, sucrose fatty acid esters, carboxymethylcellulose, and mono- and diglycerides cause metabolic disorders and gut microbiota dysbiosis in mice, raising concerns about their safety and potential role in promoting metabolic diseases.
ISU Prof.’s Research May Lead to New Treatments for Diabetes, Other Metabolic Diseases
June 20, 2024 / Metabolic Disease Research / Insulin Release / Type 2 Diabetes
Idaho State University’s research led by Lizbeth de la Cruz explores how aging affects beta cells in the pancreas and the sympathetic nervous system, aiming to develop new treatments for metabolic diseases like Type 2 diabetes.
Most liver disease in people with HIV in low and middle-income countries is caused by metabolic disorders
June 20, 2024 / HIV / Liver Disease / Metabolic Disorders
A study in the Journal of the International AIDS Society found that metabolic disorders, rather than hepatitis B and C, are the primary causes of liver disease in people with HIV in low and middle-income countries. This underscores the need for integrated care for metabolic risk factors.
MASH candidates make a splash after first drug approval
June 19, 2024 / MASH Treatment / FDA Approval / Liver Fibrosis
Madrigal Pharmaceuticals’ Rezdiffra received FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH) after a successful phase 3 trial. The drug showed significant improvements in NAFLD activity scores and fibrosis across diverse patient groups.
Common food linked to obesity, bowel disease, heart problems and a weakened immune system
June 19, 2024 / Obesity / Cardiovascular Diease
Ultra-processed foods, containing additives like emulsifiers and artificial colors, are linked to obesity, bowel disease, heart problems, and weakened immunity. Studies show these foods disrupt the gut microbiome, causing inflammation and compromising the intestinal barrier.